Impact of Early Rejection Treatment on Infection Development in Kidney Transplant Recipients: A Propensity Analysis

Table 2

Infections.

Infection type	Case (n = 169)	Control (n = 297)	Total (n = 466)
Abscess	7 (4.1%)	1 (0.3%)	8 (1.7%)
Bacteremia	14 (8.3%)	23 (7.7%)	37 (7.9%)
BK nephropathy	4 (2.4%)	3 (1.0%)	7 (1.5%)
BK viremia	9 (5.3%)	37 (12.5%)	46 (9.9%)
Candida	3 (1.8%)	2 (0.7%)	5 (1.1%)
Clostridioides difficile associated disease	9 (5.3%)	10 (3.4%)	19 (4.1%)
CMV disease	3 (1.8%)	0 (0.0%)	3 (0.6%)
CMV viremia	24 (14.2%)	40 (13.5%)	64 (13.7%)
EBV viremia	2 (1.2%)	6 (2.0%)	8 (1.7%)
Herpes simplex (disseminated)	1 (0.6%)	0 (0.0%)	1 (0.2%)
JC polyoma virus	0 (0.0%)	1 (0.3%)	1 (0.2%)
VZV (localized)	2 (1.2%)	0 (0.0%)	2 (0.4%)
Mold infection	1 (0.6%)	0 (0.0%)	1 (0.2%)
Mycobacteria	0 (0.0%)	1 (0.3%)	1 (0.2%)
Nocardia	1 (0.6%)	4 (1.3%)	5 (1.1%)
Other	11 (6.5%)	24 (8.1%)	35 (7.5%)
Pneumocystis jirovecii pneumonia (PJP)	0 (0.0%)	1 (0.3%)	1 (0.2%)
Pneumonia requiring admission	6 (3.6%)	13 (4.4%)	19 (4.1%)
Pulmonary coccidioidomycosis	2 (1.2%)	1 (0.3%)	3 (0.6%)
Pyelonephritis	10 (5.9%)	9 (3.0%)	19 (4.1%)
Symptomatic UTI	60 (35.5%)	121 (40.8%)	181 (38.9%)

All infections identified in this study, with a breakdown between the case and control cohorts. Other infections: parvovirus (4), norovirus (4), coronavirus (not SARS-CoV-2) upper respiratory tract infection (4), rhinovirus (3), parainfluenza virus (2), salmonella gastroenteritis (2), bacillus cereus colitis (2), unspecified colitis (2), influenza virus URI (1), west nile virus meningitis (1), human papilloma virus (1), hepatitis B (1), unspecified osteomyelitis (1), necrotizing fasciitis (1), human metapneumovirus (1), RSV bronchitis (1), orchitis (1), cellulitis (1), legionella pneumonia (1), enteropathogenic E. coli gastroenteritis (1).